PAREXEL Announces Change to Board of Directors
PAREXEL International, a leading innovator of global biopharmaceutical services, today announced that Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.
“Thanks to Joe’s leadership, PAREXEL has had a smooth transition from a public to private company,” said Jamie Macdonald, PAREXEL CEO. “Joe’s contributions have left an indelible mark on both our industry and the Company.”
“I’m pleased to have served on the Board during this important period of transition,” said Mr. von Rickenbach. “I have full confidence that PAREXEL’s current Board membership and organizational leadership is well positioned to take the Company to its next level of growth.”
About PAREXEL International
PAREXEL International Corporation is a leading innovator of global biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit our website and follow us on LinkedIn and Twitter.
PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005081/en/